Barclays Maintains Overweight on Indivior Pharmaceuticals, Raises Price Target to $45

Benzinga · 2d ago
Barclays analyst Glen Santangelo maintains Indivior Pharmaceuticals (NASDAQ:INDV) with a Overweight and raises the price target from $43 to $45.